PER 1.23% 8.0¢ percheron therapeutics limited

Anyone surprised ?, page-16

  1. 13,117 Posts.
    lightbulb Created with Sketch. 1370
    Bill...I think Were in safe hands....
    Mr. Mark Diamond, BSc, MBA, MAICD, has been the Chief Executive Officer and Managing Director of Antisense Therapeutics Ltd. since October 31, 2001. Mr. Diamond has broad international experience in business development in the Pharmaceutical Industry. He has over 20 years experience in the pharmaceutical and biotechnology industry. He has worked in the pharmaceutical industry for 17 years, eight of those with Faulding in Australia, Europe and in the US. Prior to joining Antisense Therapeutics, he served as Director, Product Planning and Business Development of Faulding Pharmaceutical’s Global Head Office in the US. Prior to this, he served as Senior Manager, Business Development and In-licensing within Faulding’s European operation in the UK and International Business Development Manager of Faulding in Australia. Mr. Diamond has been a Director of Antisense Therapeutics Ltd. since October 31, 2001.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
-0.001(1.23%)
Mkt cap ! $72.12M
Open High Low Value Volume
8.2¢ 8.2¢ 8.0¢ $63.52K 777.8K

Buyers (Bids)

No. Vol. Price($)
2 43377 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 97561 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.